Vaccination

New malaria vaccine results raise hopes of mass rollout

A booster dose of a new malaria vaccine maintains a high level of protection against the disease, researchers said Thursday, expressing hopes the cheap jab could be produced on a massive scale in a matter of years.

Diseases, Conditions, Syndromes

Clinical trial for rabies monoclonal antibody

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute ...

Diseases, Conditions, Syndromes

Malaria vaccine 'first to meet WHO efficacy target'

A malaria vaccine candidate tested on children in West Africa has shown an efficacy of around 77 percent, say scientists, hailing it as a breakthrough in the fight against the disease.

Diseases, Conditions, Syndromes

Researchers develop a faster, stronger rabies vaccine

Every year, more than 59,000 people around the world die of rabies and there remains no cheap and easy vaccine regimen to prevent the disease in humans. Now, researchers report in PLOS Neglected Tropical Diseases that adding ...

Diseases, Conditions, Syndromes

Researchers test Ebola vaccine for wild apes

Amid promising reports of effective Ebola vaccines for humans, a vaccine that could potentially protect endangered wild apes from deadly infectious diseases, including the Ebola virus, is being tested at the New Iberia Research ...

Diseases, Conditions, Syndromes

Rabies vaccine candidate begins human trials in Tanzania

The University of Oxford and the Ifakara Health Institute today announced the vaccination of the first participants in a Phase Ib/II trial testing a novel rabies vaccine in human volunteers in Tanzania.

Diseases, Conditions, Syndromes

Canine vaccinations effective deterrent to rabies in Africa

(Medical Xpress)—Yale School of Public Health researchers have found that annual canine vaccination campaigns not only stop the spread of rabies, a potentially deadly disease, but are cost-effective and may actually save ...

page 2 from 4